A detailed history of Segall Bryant & Hamill, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 32,061 shares of PCRX stock, worth $624,227. This represents 0.01% of its overall portfolio holdings.

Number of Shares
32,061
Holding current value
$624,227
% of portfolio
0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$11.7 - $28.46 $375,113 - $912,456
32,061 New
32,061 $482,000
Q3 2023

Nov 09, 2023

BUY
$30.68 - $40.09 $1.33 Million - $1.74 Million
43,481 Added 46.04%
137,925 $4.23 Million
Q2 2023

Aug 11, 2023

BUY
$36.12 - $47.5 $14,339 - $18,857
397 Added 0.42%
94,444 $3.78 Million
Q1 2023

May 15, 2023

BUY
$35.53 - $43.38 $41,392 - $50,537
1,165 Added 1.25%
94,047 $3.84 Million
Q4 2022

Feb 14, 2023

BUY
$38.19 - $57.45 $245,485 - $369,288
6,428 Added 7.44%
92,882 $3.59 Million
Q3 2022

Nov 14, 2022

BUY
$51.24 - $58.89 $87,671 - $100,760
1,711 Added 2.02%
86,454 $4.6 Million
Q2 2022

Aug 15, 2022

BUY
$51.49 - $81.64 $1.29 Million - $2.05 Million
25,078 Added 42.03%
84,743 $4.94 Million
Q1 2022

May 13, 2022

BUY
$60.03 - $76.49 $8,944 - $11,397
149 Added 0.25%
59,665 $4.55 Million
Q4 2021

Feb 14, 2022

BUY
$47.97 - $62.21 $132,972 - $172,446
2,772 Added 4.89%
59,516 $3.58 Million
Q3 2021

Nov 03, 2021

SELL
$54.64 - $61.3 $245,333 - $275,237
-4,490 Reduced 7.33%
56,744 $3.18 Million
Q2 2021

Aug 12, 2021

BUY
$59.18 - $69.99 $161,087 - $190,512
2,722 Added 4.65%
61,234 $3.72 Million
Q1 2021

May 13, 2021

SELL
$59.31 - $78.82 $15,361 - $20,414
-259 Reduced 0.44%
58,512 $4.1 Million
Q4 2020

Feb 12, 2021

SELL
$50.47 - $66.26 $49,309 - $64,736
-977 Reduced 1.64%
58,771 $3.52 Million
Q3 2020

Nov 13, 2020

BUY
$51.97 - $63.0 $2.03 Million - $2.46 Million
39,018 Added 188.22%
59,748 $3.59 Million
Q2 2020

Aug 14, 2020

BUY
$30.8 - $52.47 $13,890 - $23,663
451 Added 2.22%
20,730 $1.09 Million
Q1 2020

May 14, 2020

SELL
$28.4 - $50.7 $41,009 - $73,210
-1,444 Reduced 6.65%
20,279 $679,000
Q4 2019

Feb 11, 2020

SELL
$36.31 - $46.83 $42,773 - $55,165
-1,178 Reduced 5.14%
21,723 $984,000
Q3 2019

Nov 12, 2019

BUY
$35.66 - $44.99 $13,265 - $16,736
372 Added 1.65%
22,901 $871,000
Q2 2019

Aug 14, 2019

BUY
$36.57 - $47.97 $205,486 - $269,543
5,619 Added 33.23%
22,529 $0
Q1 2019

May 15, 2019

BUY
$36.47 - $42.17 $15,791 - $18,259
433 Added 2.63%
16,910 $0
Q4 2018

Feb 15, 2019

SELL
$41.31 - $52.16 $5,866 - $7,406
-142 Reduced 0.85%
16,477 $708,000
Q3 2018

Nov 14, 2018

SELL
$32.85 - $52.0 $1,708 - $2,704
-52 Reduced 0.31%
16,619 $0
Q2 2018

Aug 08, 2018

BUY
$27.5 - $39.8 $458,452 - $663,505
16,671 New
16,671 $0

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Segall Bryant & Hamill, LLC Portfolio

Follow Segall Bryant & Hamill, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.